BSECompany Update6d ago · 19 Oct 2026, 10:42 am

Enclosed herewith is the announcement under Regulation 30 of SEBI (LODR) Regulations, 2015. Kindly take the same on record.

Supriya Lifescience Ltd · 543434

✦ AI SummaryRegulatory

Supriya Lifescience Ltd has informed the stock exchanges that the matter related to judicial proceedings has been admitted by the Hon'ble Supreme Court and is listed for hearing. The court has directed that no coercive action shall be taken against the company's directors, officers, and officials, subject to certain conditions.

Analysis Scores

Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk8/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment0/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Supriya Lifescience Ltd - 543434 - Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015.

Attachments (1)

📄

38ca064c-d546-4f1e-9c25-d950f6dd6d8e.pdf

pdf

Download →
View document text
October 19, 2026 BSE Limited National Stock Exchange of India Phiroze Jeejeebhoy Towers, Limited Dalal Street, Exchange Plaza, Plot no. C/1, G Block, Mumbai- 400 001 Bandra-Kurla Complex Scrip Code: 543434 Bandra (E), Mumbai - 400 051 NSE Symbol: SUPRIYA Dear Sir/Madam, Subject: Further Update on Judicial Proceedings – Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in continuation to the earlier intimations made by the Company in relation to the captioned matter, we wish to inform you that the matter has been admitted by the Hon’ble Supreme Court and is listed for hearing. Further, the Hon’ble Supreme Court has, in the interim, directed that no coercive action shall be taken against the Directors/officers/officials of the petitioner, subject to the terms and conditions of the order passed by the Hon’ble Court. The matter is presently pending before the Hon’ble Court and is sub judice. The Company shall continue to monitor the proceedings and shall keep the Stock Exchanges and its shareholders informed of any material developments in the matter as and when received from the Hon’ble Court or otherwise in accordance with applicable laws and regulations. This is for your information and records. Thanking you, For Supriya Lifescience Limited Prachi Sathe Company Secretary & Compliance Officer Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India. Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience .com Website: www.supriyalifescience.com Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India. Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com GOVT. RECOGNISED EXPORT HOUSE